Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company based in Watertown, MA that uses a synthetic chemistry technology to discover and develop novel antibiotics. Its lead product candidate, TP-434, is a broad-spectrum IV antibiotic with potential superior potency against Gram-negative pathogens and was anticipated to enter Phase 2 clinical studies in 2010. The company also plans to advance two additional IV/oral candidates: TP-2758 for complicated urinary tract infections (cUTI) and TP-834 for community-acquired bacterial pneumonia (CABP). Tetraphase raised $45M in a Series C to fund progression of its pipeline into Phase 1 and Phase 2 clinical studies. The financing will be used specifically to advance its novel antibiotic candidates into the clinic to address drug-resistant Gram-negative infections. As part of the financing, Dr. Gullans of Excel Venture Management will join Tetraphase's board of directors. Tetraphase Pharmaceuticals develops novel antibiotics targeting drug-resistant infections and commercializes a synthetic chemistry platform developed by Dr. Andrew Myers of Harvard. The company was founded in 2006 and is based in Watertown, MA. Its pipeline includes several novel and potent antibiotic drug candidates discovered using its synthetic chemistry platform. The recent financing is intended to support advancement of those candidates toward further development. Tetraphase closed the first tranche of a $25M Series B to fund these efforts. The company has enlisted its existing investors to participate in the tranche to continue progressing its program.

Total raised

$55M

Funding rounds

2

Latest round

Series C

Latest activity

Jun 2010